Small biotech Inipharm lands $35M to take new NASH ap­proach, di­verg­ing from RNAi com­peti­tors

A year af­ter Cir­ius Ther­a­peu­tics’ lead NASH drug flopped in a large Phase IIb tri­al, the biotech’s chief busi­ness and fi­nan­cial of­fi­cer Bri­an Farmer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA